Breast Cancer Now media statements

We Respond to Breast Cancer Screening Performance Data for England 2019/20

New figures from NHS Digital, taken from the performance data on the breast screening programme for England between April 2019 and March 202...

We respond to breast cancer becoming the most common cancer globally

Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:

We respond to draft NICE decision not to recommend abemaciclib with fulvestrant for routine use on the NHS

The National Institute for Health and Care Excellence (NICE) has today announced its decision to provisionally not recommend breast cancer t...

We welcome NICE approval of ribociclib with fulvestrant for use on the NHS

The National Institute for Health and Care Excellence (NICE) has today announced its decision to approve ribociclib with fulvestrant for rou...